An analysis of the pattern and profile of adverse drug reactions reported at a tertiary care teaching hospital in Kerala, India: a retrospective record based observational study
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20183477Keywords:
Adverse drug reactions, Causality, PharmacovigilanceAbstract
Background: Adverse drug reactions (ADRs) are an important concern in modern therapeutics. Due to limitations in identifying ADRs during research phase, organized post marketing studies are essential. However, there are only few recent studies on this subject available in India. Hence this study was done in a tertiary care hospital in South Kerala to evaluate the profile and causality of ADRs.
Methods: The details of patients who developed ADRs during the period from October 2016 to November 2017 were collected. Data collection was done using the suspected drug reactions monitoring form by CDSCO used under PvPI and a retrospective observational cross-sectional analysis was done. The profile and causality of ADRs were evaluated.
Results: The total number of ADR events reported was 300. 179 ADRs were hypersensitivity reactions (Aronson Type B) and the remaining 121 reactions were Type A reactions. The individual drug class causing majority of the ADRs was antibiotics (36%). Commonest significant dose related ADR was bleeding (7%) caused by combined use of antiplatelets and anticoagulants. The organ system most affected as per SOC classification was skin and appendages (56%). Causality assessment revealed that majority (76%) belonged to “probable” category, whereas 23.6% were of “possible” type.
Conclusions: The development of ADRs can significantly affect treatment course – interruption of drug therapy, use of additional drugs and prolonged hospital stay. Employing monitors dedicated to ADR detection and education of prescribers to closely monitor patients can help manage ADRs effectively.References
World Health Organization. Safety of medicines. A guide to detecting and reporting adverse drug reactions. Why health professionals need to take action. Geneva World Health Organization. 2002. Available at: http://apps.who.int/medicinedocs/en/d/Jh2992e. Accessed 9 May 2018.
Jerry Avorn. The Role of Therapeutic Agents in Modern Medicine B: Drug Risks. In: C.J. van Boxtel, B. Santoso and I.R. Edwards, eds. Drug Benefits and Risks: International Textbook of Clinical Pharmacology, revised 2nd Ed. Amsterdam: IOS Press; 2008:10-13.
The WHO Global ICSR Database System: Basic Facts. Available at: www.who.int/medicines/regulation/medicines-safety/about/drug_monitoring_prog/en. Accessed 13 May 2018.
Pharmacovigilance programme of India. List of ADR monitoring centers. Available at: http://www.ipc.gov.in/PvPI/adr.html. Accessed on 2 March 2018.
Pharmacovigilance programme of India 2010. CDSCO, Ministry of Health and Family Welfare, Government of India. 2010. Available at: http://cdsco.nic.in/pharmacovigilance.html. Accessed on 2017 March 25.
Aronson J, Ferner RE. Joining the DoTS: The new approach to classifying adverse drug reactions: BMJ 2003;327(1):1222.
Medical Dictionary for Regulatory Activities. Available at: http://www.meddramsso.com. Accessed o14 May 2018.
Agaard L, Strandell J, Melskens L, Petersen PS, Holme Hansen E. Global patterns of adverse drug reactions over a decade: Analyses of spontaneous reports to VigiBase™. Drug Saf. 2012;35:1171-82.
Doshi MS, Patel PP, Shah SP, Dikshit RK. Intensive monitoring of adverse drug reactions in hospitalized patients of two medical units at a tertiary care teaching hospital. J Pharmacol Pharmacother. 2012;3:308-13.
Arulmani R, Rajendran SD, Suresh B. Adverse drug reaction monitoring in a secondary care hospital in South India. Br J Clin Pharmacol. 2008;65:210-6.
Giardina C, Cutroneo PM, Mocciaro E, Russo GT, Mandraffino G, Basile G, et al. Adverse Drug Reactions in Hospitalized Patients: Results of the FORWARD (Facilitation of Reporting in Hospital Ward) Study. Frontiers in Pharmacol. 2018 Apr 11;9:350.
Kamalaraj R, Revathy J, Vijey Aanandhi M, Murugan M, Ramanakumar KPV. Incidence, severity and financial burden associated with suspected unexpected serious adverse reactions (SUSARs) that arise in clinical trials. Asian J Pharm Clin Res. 2012;5:198-201.
Sriram S, Ghasemi A, Ramasamy R, Devi M, Balasubramanian R, Ravi TK. Prevalence of adverse drug reactions at a private tertiary care hospital in south India. J Res Med Sci. 2011;16:16-25.
